Showing 4311-4320 of 7638 results for "".
- derma e Launches Firming and Deep Wrinkle Productshttps://practicaldermatology.com/news/derma-e-launches-firming-and-deep-wrinkle-products/2459020/derma e® launched its new Firming DMAE Eye Lift and Deep Wrinkle Peptide Moisturizer SPF 30. “derma e® is raising the bar for natural skin care performance with the launch of these two new products,” says Jennifer Norman, Vice President of Marketing for derma e®. “In pre-launch consumer testing, F…
- ASDSA Names 2014 Patient Safety Hero Award Winnershttps://practicaldermatology.com/news/asdsa-named-2014-patient-safety-hero-award-winners/2459025/Honoring physicians and dermatologic societies whose notable efforts for greater patient safety in cosmetic procedures have made a difference last year, the American Society for Dermatologic Surgery Association (ASDSA) recently named the 2014 winners of its annual Patient Safety Hero Awards. The Mi…
- Dr. Zein Obagi's New Book Presents the Art and Science of Skin Healthhttps://practicaldermatology.com/news/dr-zein-obagis-new-book-present-the-art-and-science-of-skin-health/2459023/Zein Obagi, MD, founder of ZO Skin Health, Inc., has published a new book, The Art of Skin Health Restoration and Rejuvenation: The Science of Clinical Practice, Second Edition (CRC Press, Dec 2014). In it, he reveals the Zein Obagi System of Skin Classification that specifically addresses the vari…
- BioD Receives US Patent for Placental Tissue Technology for Improved Wound Care and Healinghttps://practicaldermatology.com/news/biod-receives-us-patent-for-placental-tissue-technology-for-improved-wound-care-and-healing/2459024/BioD, LLC received its first patent for one of its platform tissue technologies. On January 13, 2015, the US Patent and Trademark Office issued US Patent Number 8,932,805, “Birth Tissue Material and Method of Preparation.” The patent covers the company’s BioDFactor® Viable Tissue Matrix product fam…
- Celsus Therapeutics Receives FDA Allowance of IND in Atopic Dermatitishttps://practicaldermatology.com/news/celsus-therapeutics-receives-fda-allowance-of-ind-in-atopic-dermatitis/2459026/Celsus Therapeutics will expand its clinical program in atopic dermatitis in the US, now that the FDA has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The Company plans to initiate enrollment of a Phase II…
- Dermira and UCB Announce Start of Phase 3 Program for Cimzia® (Certolizumab Pegol) in Psoriasishttps://practicaldermatology.com/news/dermira-and-ucb-announce-start-of-phase-3-program-for-cimzia-certolizumab-pegol-in-psoriasis/2459027/Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biopharmaceutical leader (Euronext: UCB), announced today that the first patients have been dose…
- Oculus Innovative Sciences Launches IntraDerm Pharmaceuticals, New Dermatology Divisionhttps://practicaldermatology.com/news/oculus-innovative-sciences-launches-intraderm-pharmaceuticals-new-dermatology-division/2459028/Oculus Innovative Sciences, Inc., a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, has launched a new division, IntraDerm Pharmaceuticals. IntraDerm Pharmaceuticals is intended to develop and commerciali…
- XTRAC Offering Rebate for Excimer Laser Treatmentshttps://practicaldermatology.com/news/xtrac-offers-coupon-for-vitiligo-treatments/2459029/PhotoMedex is offering a limited-time rebate for patients treated with the XTRAC Excimer Laser from January 1 through March 31, 2015. The rebate is worth up to $100 per treatment and can be used to offset the costs of insurance deductibles and co-pays for patients (for up to 10 treatments per cours…
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-threatening condition …
- LEO Pharma Submits NDA for Aerosol Foam for Psoriasis to FDAhttps://practicaldermatology.com/news/leo-pharma-submits-nda-for-aerosol-foam-for-psoriasis-to-fda/2459033/LEO Pharma has submitted a New Drug Application to FDA for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. The novel aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed with the a…